How do novel agents affect allogeneic transplantation in CLL?
The differences between biological and chronological age, with their implications on AML treatment
Benefits of deacetylase inhibitors for leukemia therapy
The multi-cohort SCHOLAR-1 study of refractory aggressive DLBCL
What types of post-transplant complications does the biobank project aim to improve?
Regis Peffault de Latour